All News

alcohol%20glasses-919071__180.jpg (keep)

ICYMI: RA Disease Activity and Alcohol Use

Jack Cush, MD

Despite its well known toxicities, alcohol is known to be antiinflammatory. The effects of alcohol use in rheumatoid arthritis (RA) is less known, but a recent study suggests that alcohol consumption was dose-dependently associated with lower disease activity and higher health-related quality of life in RA patients.

Read Article
RheumNow Podcast square

Scleroderma – Thick and Thin (6.30.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week from RheumNow.com. This week focuses on parodoxical psoriasis, scleroderma outcomes and subsets, and alopecia areata therapy.

Read Article
back, LBP, spine, AS

Opioids Ineffective in Acute Lower Back and Neck Pain

EurekAlert!

A randomised controlled trial including 347 participants with lower back or neck pain found there was no benefit of taking opioid pain relievers compared to placebo. 

Read Article
FDA.Safety.jpg

FDA Delays Bimekizumab Decision, Again

Jack Cush, MD

Editor's Note: please note the error in the original report has been corrected to read: UCB affirms there are no open information requests from the FDA regarding the BLA for bimekizumab or bimekizumab manufacturing.

Read Article
child.guttate.psoriasis

Paradoxical Psoriasis in Kids Taking TNF Inhibitors

Jack Cush, MD

A multicenter cohort study reported a large cohort of pediatric patients receiving TNF inhibitor therapy complicated by psoriasis, regardless of treatment indication or the specific TNF inhibitor.

Read Article
arttemp.jpg

TitAIN Study: Secukinumab Efficacy in Giant Cell Arteritis

Jack Cush, MD

A phase 2 trial has demonstrated the efficacy of secukinumab, an anti-interleukin-17A monoclonal antibody, in patients with active giant cell arteritis (GCA).

Read Article
RheumNow Podcast square

What is Colchicine Worth? (6.23.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and reports from the past week on RheumNow.com. This week a new colchicine FDA approval, rising rate of IgG4 related disease and what's the safest biologic?

Read Article
price%20of%20pills.jpg

Why Patients Don't Take Medicines

CDC

About 60% of adults aged 18 and over reported taking at least one prescription medication in 2021, with 36% reporting taking three or more. Out-of-pocket costs on retail drugs rose 4.8% to $63 billion in 2021.

Read Article
FDA,approved,stamp,blue

FDA Approves Colchicine for CV Prevention

Jack Cush, MD

The FDA has approved colchicine (Lodoco) for cardiovascular prevention in adults with established atherosclerotic disease or multiple risk factors, making it the first anti-inflammatory medicine with such an indication.

Read Article
Metanalysis of 62 RCTs, 16 LTEs, 82 366 Pt-Yrs JAK exposure. JAKi malignancy incid rate = 1.15/100 PYs in RCTs (1.26/100PYs overall). Network meta-analyses show no diff betw JAK & PBO or MTX in NMSC, but signif increased malignancy risk (IRR 1.50) https://t.co/ANa7zYmhPx

Links:

Dr. John Cush RheumNow ( View Tweet)

Check SSc-ILD Patients on Nintedinib for Malnutrition During nintedanib treatment for interstitial lung disease associated with SSc-ILD, clinicians prescribing the drug should be watchful for an unusual, indirect side effect, trial data suggested. https://t.co/TmN71qSCb2 https://t.co/TVU2qcPdZE

Links:

Dr. John Cush RheumNow ( View Tweet)
Paradoxical Psoriasis in Kids Taking TNF Inhibitors A multicenter cohort study reported a large cohort of pediatric patients receiving TNF inhibitor therapy complicated by psoriasis, regardless of treatment indication or the specific TNF inhibitor. https://t.co/9WxkAt8NnS https://t.co/sGvb1eZWE0

Links:

Dr. John Cush RheumNow ( View Tweet)
UK MHRA reminder that NSAIDs are: - contraindicated in the 3rd trimester of pregnancy (>28wks) - >20 wks - assoc w/ increased risk of oligohydramnios & fetal renal dysfunction MDs should avoid NSAIDs in pregnancy after wk 20 https://t.co/u3fTnuoF17 https://t.co/b2b5XThe1i

Links:

Dr. John Cush RheumNow ( View Tweet)
Check SSc-ILD Patients on Nintedinib for Malnutrition During nintedanib treatment for interstitial lung disease associated with SSc-ILD, clinicians prescribing the drug should be watchful for an unusual, indirect side effect, trial data suggested. https://t.co/5Q3xCwLvPa https://t.co/mGD3DCYZR0

Links:

Dr. John Cush RheumNow ( View Tweet)
Paradoxical Psoriasis in Kids Taking TNF Inhibitors A multicenter cohort study reported a large cohort of pediatric patients receiving TNF inhibitor therapy complicated by psoriasis, regardless of treatment indication or the specific TNF inhibitor. https://t.co/f1KmICaGNF https://t.co/N0jxIJbv7Q

Links:

Dr. John Cush RheumNow ( View Tweet)
Paradoxical PsO (PP) studied in 2867 RA & 5316 SpA pts. 136 (1.7%) had paradox. Rxn, median 12 mos post TNFi [pustular (60%) or palmoplantar (31%)]. 73% PP favorably switched to other TNFi 46% or non-TNFi 27%. RA PP took SSZ, HCQ, LEF; SpA PP more smokers https://t.co/iYM3EOdSSM https://t.co/sruLP9adx3

Links:

Dr. John Cush RheumNow ( View Tweet)
Arborviral infx w/ rituximab? 21 RTX pts dx w/ arboviral neuroinvasive Dz, (encephalitis, acute flaccid myelitis); 79% died. B cell depletion impairs immunity & spread of West Nile Virus, serologic Ab Dx tests; thus if suspected, order RT-PCR tests https://t.co/I6A8F4Kx7a https://t.co/njyciZFn52

Links:

Dr. John Cush RheumNow ( View Tweet)
Why Patients Don't Take Medicines This report examines the characteristics of adults aged 18–64 who took prescription medication in the past 12 months and did not take medication as prescribed due to cost. https://t.co/zuPgMjKYbh https://t.co/62cG9LDYWi

Links:

Dr. John Cush RheumNow ( View Tweet)
Indian study of 943 AIRD patients (43% RA) starting biologics or JAKi, had TB screening with IGRA assay. 125 pts were IGRA pos. and had LTBI; 124/125 received anti-TB prophylaxis. IGRA Accuracy in predicting absence of TB reactivation = 99.6% https://t.co/KI9vGWpS59 https://t.co/Ne33P51koD

Links:

Dr. John Cush RheumNow ( View Tweet)
Abatacept Safety Outcomes Across 7 European Registries A multinational registry analysis of rheumatoid arthritis receiving abatacept has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy. https://t.co/hAj3UZjbHJ https://t.co/eQHjEgelRM

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×